Omega 3 fatty acids in bipolar disorder:
a preliminary double-blind, placebo-controlled trial

Stoll AL, Severus WE, Freeman MP, Rueter S,
Zboyan HA, Diamond E, Cress KK, Marangell LB.
Brigham and Women's Hospital,
Department of Psychiatry,
Harvard Medical School, Boston, Mass, USA.
Arch Gen Psychiatry 1999 May; 56(5):407-12


BACKGROUND: Omega3 fatty acids may inhibit neuronal signal transduction pathways in a manner similar to that of lithium carbonate and valproate, 2 effective treatments for bipolar disorder. The present study was performed to examine whether omega3 fatty acids also exhibit mood-stabilizing properties in bipolar disorder. METHODS: A 4-month, double-blind, placebo-controlled study, comparing omega3 fatty acids (9.6 g/d) vs placebo (olive oil), in addition to usual treatment, in 30 patients with bipolar disorder. RESULTS: A Kaplan-Meier survival analysis of the cohort found that the omega3 fatty acid patient group had a significantly longer period of remission than the placebo group (P = .002; Mantel-Cox). In addition, for nearly every other outcome measure, the omega3 fatty acid group performed better than the placebo group. CONCLUSION: Omega3 fatty acids were well tolerated and improved the short-term course of illness in this preliminary study of patients with bipolar disorder.
Bipolar disorder
Protein kinase C
Essential fatty acids
Omega-3 plus antidepressant
Aging, Omega-3 fatty acids and the brain
Omega-3 for borderline personality disorder
Omega-3, inflammation/autoimmune diseases
Ethyl-eicosapentaenoate as an antidepressant
Unsaturated fatty acid deficiency and dopamine
Folic acid and PUFAs prevent depression and dementia

and further reading

Future Opioids
BLTC Research
Utopian Surgery?
The Abolitionist Project
The Hedonistic Imperative
The Reproductive Revolution
Critique of Huxley's Brave New World

The Good Drug Guide
The Good Drug Guide

The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family